Innovation in Preleukemia
October 7, 2021
Myelodysplastic syndrome (MDS) has historically been considered a “graveyard” for drug development - other than hypomethylating agents, there have been no new therapies approved in more than a decade. Yet, new understanding of the genetics of the disease and its relationship to acute myeloid leukemia (high-risk MDS is often referred to as preleukemia) have sparked a wave of interest in the field, giving patients with this form of blood cancer reason to hope.
Syros’ CEO, Nancy Simonian, and CMO, David Roth, join The Pharma Letter podcast for a discussion about the HR-MDS treatment landscape, Syros’ investigational product candidate, tamibarotene, an oral first-in class selective RARα agonist, and provide insights to key steps in the drug development process, including the importance of listening to patients’ perspectives.
Listen to the podcast here.